Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,578.30 INR | +1.35% |
|
+5.69% | -10.49% |
11/07 | Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy | MT |
30/06 | India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma | RE |
Company Valuation: Mankind Pharma Limited
Data adjusted to current consolidation scope
Fiscal Period: March | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
Capitalization 1 | 9,21,654 | 10,64,139 | - | - |
Change | - | 15.46% | - | - |
Enterprise Value (EV) 1 | 8,89,053 | 10,62,777 | 11,14,848 | 10,91,244 |
Change | - | 19.54% | -1.46% | -2.12% |
P/E ratio | 48.3x | 49.3x | 51x | 39x |
PBR | 9.84x | 6.98x | 6.58x | 5.71x |
PEG | 1x | 15.46x | 8x | 1.3x |
Capitalization / Revenue | 8.92x | 8.2x | 7.18x | 6.38x |
EV / Revenue | 8.6x | 8.71x | 7.52x | 6.54x |
EV / EBITDA | 35.1x | 35.2x | 28.9x | 24.2x |
EV / EBIT | 41.6x | 44.3x | 37x | 30.2x |
EV / FCF | 48.4x | 55.8x | 43.6x | 36.5x |
FCF Yield | 2.07% | 1.79% | 2.29% | 2.74% |
Dividend per Share 2 | - | 9 | 7.8 | 10.42 |
Rate of return | - | 0.35% | 0.3% | 0.4% |
EPS 2 | 47.68 | 49.2 | 50.52 | 66.09 |
Distribution rate | - | 19% | 15.4% | 15.8% |
Net sales 1 | 1,03,348 | 1,22,074 | 1,48,236 | 1,66,918 |
EBITDA 1 | 25,351 | 30,179 | 38,630 | 45,133 |
EBIT 1 | 21,368 | 23,967 | 30,139 | 36,172 |
Net income 1 | 19,129 | 19,910 | 20,959 | 27,142 |
Net Debt 1 | -32,600 | 62,377 | 50,709 | 27,105 |
Reference price 2 | 2,300.75 | 2,578.30 | 2,578.30 | 2,578.30 |
Nbr of stocks (in thousands) | 4,00,588 | 4,12,729 | - | - |
Announcement Date | 15/05/24 | 21/05/25 | - | - |
1INR in Million2INR
Estimates
P/E ratio, Detailed evolution
P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
---|---|---|---|---|---|---|
54.29x | 9.2x | 35.53x | 0.35% | 1.24TCr | ||
37.3x | 12.31x | 28.09x | 0.75% | 71TCr | ||
15.04x | 4.2x | 11.56x | 3.34% | 38TCr | ||
27.26x | 6.59x | 13.78x | 3.42% | 34TCr | ||
16.85x | 6.08x | 12.14x | 3% | 31TCr | ||
14.15x | 3.48x | 8.6x | 3.84% | 26TCr | ||
17.15x | 4.63x | 11.21x | 3.26% | 24TCr | ||
22.3x | 4.15x | 12.2x | 2.28% | 22TCr | ||
10.68x | 3.46x | 7.48x | 3.86% | 21TCr | ||
22.58x | 5.78x | 11.22x | 3.25% | 16TCr | ||
Average | 23.76x | 5.99x | 15.18x | 2.73% | 28.29TCr | |
Weighted average by Cap. | 23.23x | 6.75x | 15.58x | 2.64% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MANKIND Stock
- Valuation Mankind Pharma Limited
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition